Zobrazeno 1 - 10
of 137
pro vyhledávání: '"J Greeve"'
Publikováno v:
Journal of Lipid Research, Vol 37, Iss 9, Pp 2001-2017 (1996)
Apolipoprotein (apo) B exists in two forms, the full length protein apoB-100 and the carboxyterminal-truncated apoB-48 that is synthesized in the intestine due to editing of the apoB mRNA which generates a premature stop codon. To determine whether g
Externí odkaz:
https://doaj.org/article/96752c68c7e0402aac4012d545e76656
Publikováno v:
Journal of Lipid Research, Vol 34, Iss 8, Pp 1367-1383 (1993)
Two different isoproteins are encoded by the apolipoprotein (apo) B gene, apoB-48 and apoB-100. ApoB-48, core component of intestinally derived chylomicrons, has an accelerated plasma turnover as compared with the full-length protein apoB-100. A post
Externí odkaz:
https://doaj.org/article/8e6bc2850d4b4b169e388d82a3219a7b
Publikováno v:
Journal of Lipid Research, Vol 33, Iss 3, Pp 419-429 (1992)
The contribution of the low density lipoprotein (LDL) receptor to the removal of chylomicron remnants was determined in vitro and in vivo by using interventions that up- or down-regulate the LDL receptor but not the LDL receptor-related protein (LRP)
Externí odkaz:
https://doaj.org/article/6f03a27a98a042349d75611b27348b23
Autor:
Thomas J. Ettrich, Jens Atzpodien, Stephan Kanzler, Swen Wessendorf, Swantje Held, Petra Buechner-Steudel, Axel Florschütz, D Nörenberg, Max Seidensticker, Anke Reinacher-Schick, Jorge Riera-Knorrenschild, Dominik Paul Modest, Michael Geissler, J. Greeve, Uwe M. Martens, Volker Heinemann, Sebastian Stintzing, Andrea Tannapfel, Annika Kurreck, Thomas Seufferlein
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose In mCRC, disease dynamics may play a critical role in the understanding of long-term outcome. We evaluated depth of response (DpR), time to DpR, and post-DpR survival as relevant endpoints. Methods We analyzed DpR by central review of compute
Autor:
Uwe M. Martens, Swen Wessendorf, Heinemann, Petra Buechner-Steudel, J. Greeve, Axel Florschütz, Thomas J. Ettrich, Andrea Tannapfel, Anke Reinacher-Schick, Thomas Seufferlein, Michael Geissler, Swantje Held, Jens Atzpodien, Jens Ricke, Max Seidensticker, Jorge Riera-Knorrenschild, Stephan Kanzler, Dominik Paul Modest, Dominik Nörenberg
Publikováno v:
Journal of Clinical Oncology. 37:3401-3411
PURPOSE This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II trial in patients with untreated
Autor:
Sebastian Stintzing, Michael Geissler, J. Greeve, Volker Heinemann, Petra Buechner-Steudel, Annika Kurreck, Jens Atzpodien, Nörenberg Dominik, Swen Wessendorf, Anke Reinacher, Swantje Held, Axel Florschütz, Thomas J. Ettrich, Dominik Paul Modest, Thomas Seufferlein, Stephan Kanzler, Uwe M. Martens, Andrea Tannapfel, Max Seidensticker, Jorge Riera-Knorrenschild
Publikováno v:
Journal of Clinical Oncology. 38:e16055-e16055
e16055 Background: In patients with mCRC, dynamics of response and disease progression may play a critical role in the understanding of long-term outcome. Depth of response (DpR), time to DpR and post-DpR survival represent innovative endpoints to ev
Autor:
Thomas J. Ettrich, Swen Wessendorf, Swantje Held, Axel Florschütz, Jens Atzpodien, Dominik Noerenberg, Max Seidensticker, Uwe M. Martens, Jorge Riera-Knorrenschild, Andrea Tannapfel, Stephan Kanzler, J. Greeve, Volker Heinemann, Dominik Paul Modest, Jens Ricke, Anke Reinacher-Schick, Petra Buechner-Steudel, Michael Geissler
Publikováno v:
Journal of Clinical Oncology. 37:3530-3530
3530 Background: The VOLFI trial demonstrated improved objective response rate (ORR) with the addition of pmab to modified triplet chemotherapy with FOLFOXIRI in a 2:1 (63 patients FOLFOXIRI plus pmab; 33 patients FOLFOXIRI) randomized, controlled, p
Autor:
Axel Florschütz, Thomas J. Ettrich, Anke Reinacher-Schick, Swen Wessendorf, J. Greeve, Thomas Seufferlein, Swantje Held, Volker Heinemann, Michael Geissler, Stephan Kanzler, Jorge Riera-Knorrenschild, Uwe M. Martens, Dominik Paul Modest, Andrea Tannapfel
Publikováno v:
Journal of Clinical Oncology. 37:3511-3511
3511 Background: This trial evaluated activity and safety of mFOLFOXIRI + panitumumab vs FOLFOXIRI in ECOG 0-1, primarily non-resectable mCRC patients. The final primary endpoint was presented at ASCO and ESMO 2018. Now we report for the first time t
Autor:
Anke Reinacher-Schick, J. Riera Knorrenschild, Andrea Tannapfel, Michael Geissler, Uwe M. Martens, T. Klingler, J. Greeve, Volker Heinemann, Stephan Kanzler, Thomas Seufferlein, Swantje Held
Publikováno v:
Annals of Oncology. 29:viii150
Publikováno v:
Zeitschrift für Gastroenterologie. 56:e260-e260